The FDA approved PRP-OMP for routine administration to infants beginning at 2 months of age
On Dec. 13, 1990, the U.S. Food and Drug Administration (FDA) approved Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) (PRP-OMP), manufactured by Merck Sharp and Dohme for use with infants.
Haemophilus influenzae type b (Hib) is the leading cause of invasive bacterial disease among children in the United States.
Tags:
Source: U.S. Centers for Disease Control and Prevention
Credit:
